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Abstract  
Medicines package leaflets (PL) need to be clear and comprehensible, according to legal recommendations. Abbreviations and 
symbols (A&S) are not recommended since their use may lead to misunderstandings and medication errors. Objectives: 1) 
identify, typify and quantify all A&S in a large sample of Portuguese PL, 2) detect discrepancies between these A&S and 
regulations, and 3) assess how educated individuals interpret A&S found in Portuguese PL. Methods: descriptive and exploratory 
study. Descriptive study - 531 PL were visually inspected in order to identify all A&S and a computer tool was programmed to 
count these A&S. All A&S were typified according to classificatory groups (e.g. abbreviations of diseases names) and evaluated 
according to the regulations. Exploratory study - the interpretation of 373 A&S by 26 undergraduates was assessed with a 
questionnaire. Results: 828 different A&S were identified (6407 occurrences). The average number of A&S per PL was 12.1 
(SD=13.1). Thirteen classificatory groups were built. Non-compliant A&S were found. Only a very low percentage of responses 
was correct (9.9%). Conclusion: A&S were prevalent in PL, contrary to the international recommendations. A significant number 
of technical A&S was unfamiliar to a group of educated people. Automatic tools and procedures regarding these readability 
features should be developed in order to validate PL’s compliance with regulations. 
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1. Introduction 
In the European Union, all medicines must be accompanied by a package leaflet (PL).1 PL must contain 
information on 1) What X is and what it is used for, 2) What you need to know before you <take> <use> X, 3) How 
to <take> <use> X, 4) Possible side effects, 5) How to store X, and 6) Contents of the pack and other information (X 
= the name of the medicine),2 and must be clear and legible to ensure patients’ comprehension.3 PL are usually 
consulted by patients, potential users of medicines and health professionals.4,5 It is well established that the patients 
with a low literacy level have more difficulty in understanding health information.6-8
In Europe, the PL are developed by the marketing authorization holders and approved by the national medicine 
agencies of each European country or in some cases by the European Medicine Agency (EMA).1-3 According to the 
requirements of the EMA, abbreviations, should not in general be used in medicinal PL. Similarly, scientific 
symbols should be avoided, due to the risk of misinterpretations (e.g. ">" mistaken for "<").3,9 Many studies report 
that the use of abbreviations in PL is unsuitable for the users’ compreension.10,11,12 The following abbreviations (A) 
and/or symbols (S) (A&S) are among those explicitly recommended not to be used: μg (or micrograms: risk of 
misinterpretation as mg), U (or units: risk of misinterpretation as zero or four), numerical dose and unit of measure 
running together (e.g. 10mL: risk of misinterpretation as 100 or 1000), and abbreviations of certain active substances 
(e.g. AZT: risk of misinterpretation as zathioprine or aztreonam) - in these cases, the use of mcg, units, 10mL, and 
zidovudine is recommended instead, respectively. Fractions should also be avoided (e.g. ½: risk of misinterpretation 
as 1 or 2). 13-15
There are convincing reports on medication errors caused by the inadequate use of A&S.16,17 For instance, among 
the 643,151 medication errors reported in the MEDMARX program 2004-2006, 29,974 (4.7%) were related to the 
inadequate use of A&S by health professionals, which in some cases caused the patient’s death.16 In Portugal, 
21,594 cases of intoxication were reported, and 3,085 of these (14.2%) were related to the incorrect use of medicines 
(2011). The exact number of events resulting from the patients’ misinterpretations of A&S is however not known.18
The aims of this study were: 
x To identify, quantify and classify A&S in an extensive sample of package leaflets (Objective 1). 
x To detect discrepancies between these A&S and the legal requirements (Objective 2). 
x To assess educated peoples’ interpretation of a sample of A&S (Objective 3). 
This paper is organized as follows. In section 2 we provide the details about the methods followed in the studies 
conducted, in section 3 we present our major results, in section 4 the results are discussed, and practical implications 
and limitations are identified. We conclude in section 5 with some final remarks. 
2. Methods 
A descriptive study was conducted in order to address objectives 1 and 2, and an exploratory study was carried 
out so as to address objective 3. 
2.1 Descriptive study 
All names of brand medicines mentioned in the Portuguese Prescribing Guide19 were collected in a MS Excel file.
This national guide is developed in collaboration with Infarmed (the Portuguese medicine agency) and describes the 
majority of the Portuguese medicines. A sample of 531 (28.5%) brand names of medicines was randomly selected 
from all (100%) the branded names mentioned in this guide.19 The 531 PL were consulted in Infomed (the 
Portuguese public database with information on medicines).20 The sample size was conveniently defined.21 PL of 
generic medicines were excluded because these are identical or very similar to the PL of branded medicines.1
Firstly, all A&S were manually identified in each PL, since the scientific A&S present in glossaries of medicinal 
bibliographic sources19,22,23 were not always identical to those used in the PL.  
Secondly, these A&S were post-hoc classified as follows: 
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x Units of measure (e.g. mg/5mL) (Group 1); 
x Chemical symbols of excipients, package materials, etc. (e.g. HDPE: high-density polyethylene) (Group 2); 
x Fractions or numbers in association with symbols or letters (e.g. <1/10, 8/8 h) (Group 3); 
x Names of diseases (e.g. ADHD: attention deficit hyperactivity disorder) (Group 4); 
x Microorganisms, such as bacteria or viruses (e.g. HPV: human papillomavirus) (Group 5); 
x Drug names or therapeutic-related information (e.g. ZDV: zidovudine) (Group 6); 
x Information on drug administration (e.g. i.v.: intravenous) (Group 7); 
x Information on anatomical and/or physiological issues (e.g. LDL: low-density lipoprotein) (Group 8); 
x Enzymes (e.g. G6DP: glucose-6-phosphate dehydrogenase) (Group 9); 
x Mathematical or pharmacokinetic symbols (e.g. "+", AUC: area under the curve) (Group 10); 
x Marks on the surfaces of medicines (e.g. logotypes) (Group 11); 
x Items of common use (e.g. "®" for trademark or CE for European products) (Group 12); 
x Other A&S not related to any of the above categories (e.g. EMA for European Medicine Agency) (Group 13). 
Two pharmacists coded the A&S through a consensus process. The codifications were based on reliable 
bibliographic sources.19,22,23 Furthermore, the A&S with full correspondence in a language other than Portuguese, 
such as English or Latin were quantified (e.g. NSAID: non-steroidal anti-inflammatory drugs instead of AINE: anti-
inflamatório não esteróide).
Thirdly, a software application (PreText) was programmed to automatically identify and count the A&S.24 The 
reliability of the tool was checked during the PL analysis, and at the end of the process 20 PL (3.7%) were 
randomized to be double-checked. No errors were detected. 
The medicines of the sampled PL were classified as follows: 1) prescription-only or over-the-counter (OTC) 
medicines, 2) medicines approved via a centralized (or a single marketing authorization that is valid in all EU 
countries) or non-centralized procedures (all the other types of approval procedures),25 3) medicines with different 
routes of administration, and 4) medicines from different therapeutic groups, in accordance to the data available in 
Infomed.20 These 4 classificatory groups were selected because: 1) OTC medicines may be freely acquired without 
the intervention of a health professional,1,10 and thus the clarity of the information of the PL of OTC medicines is 
especially relevant, 2) PL of medicines approved via a centralized procedure25 are available in all European 
countries, and therefore our study may be of particular relevance in this group, given the potential for generalization 
of our results and/or procedures to PL existing in other European countries, and 3) some routes and therapeutic 
groups may be more hazard than others (e.g. dermatologic vs. parenteral medicines).26
2.2 Exploratory interpretation study  
An exploratory study to assess participants’ interpretation of a set of medicinal A&S was conducted using a 
questionnaire. All selected participants were university undergraduates from non-biomedical studies. 
2.2.1 Questionnaire development 
A questionnaire was built to collect participants' socio-demographic data and interpretation on the sampled A&S. 
Firstly, a total of 525 A&S were conveniently identified in 3 glossaries of standard medical literature,19,22,23 and 
secondly, in order to limit the size of the questionnaire, a random sample of 373 A&S (ca. 70%) was selected. 362 
of the 373 A&S (97%) were classified as abbreviations and 11 (3%) as symbols. Each of these A&S was browsed in 
a public database of current Portuguese texts (extracted, for instance, from newspapers), containing more than 221 
million words in order to check if they were familiar/frequent in the current language.27 According to the results of 
this study: 29 A&S (10.4%) occurred once in one million words and the remaining A&S were not found in the 
database. This confirms the A&S under evaluation have a low frequency in the language, if they exist at all, and 
tend in general not to be used in non-technical texts. 
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The questionnaire used a tabular format: 1) the A&S (e.g. MAO) were presented in the first column, 2) the 
correspondent full meaning of each A&S (e.g. monoamine oxidase inhibitor) was presented in the second column, 
3) participants were instructed to signal in the third column whether they knew the meaning of the A&S ("yes" or 
"no") , and 4) if the answer was "yes", they were asked to give a brief description of the meaning of the A&S in the 
fourth column. Null answers and wrong explanations were classified as incorrect and all the others as correct. Two 
specialist independently re-checked the correct answers. The fulfillment of questionnaire by the participants was not 
time limited, and all the participants fulfilled the questionnaire in less than 1 h.  
The questionnaire comprised 23 control questions (one per page) to check participants’ attention. The control 
items were selected from common A&S available in the PL (e.g. Fig. or figure). The familiarity/frequency of the 
control A&S was cheeked in the same public database of current Portuguese (10 control A&S with 1 to 10 
occurrence per million, and 13 control A&S with 10 or more occurrences per million).27. The tested and control A&S 
were alphabetical ordered. The questionnaire was divided into two approximately equal parts (186/187 questions 
plus 11/12 controls per questionnaire) and administered in two classes of undergraduates during the same week. 
Written instructions were given in the first page of questionnaire and any remaining questions were answered by the 
researcher. All data were anonymous and confidential. 
2.2.2 Participants’ selection 
University undergraduates from non-biomedical studies (> 18 years) were invited to fill in the questionnaire. 
After the procedures were explained, the participants willing to participate were enrolled in the study, with no 
dropouts. These participants were selected because they present a higher literacy level than that of the majority of 
the Portuguese population, since only less than 75% of the Portuguese population completed the 9th grade (2011 
census data),28 and at the same time they are expected to lack specific health knowledge. In order to avoid biases, the 
following exclusion criteria were set: participants with possible specific health knowledge; non-native Portuguese 
speakers. The specific health knowledge was assessed inquiring if participants had prior 1) formal instruction in 
health, 2) experience in taking care of patients, 3) working experience in healthcare, or 4) any other situation that 
they considered might exceptionally have promoted their health knowledge. Overall, 26 participants were enrolled 
in this study (October 2012). The sample size of this study was based on the recommendations of the European 
Guideline on the readability of the labelling and package leaflet, i.e. enrolment of at least 20 participants.3,29
2.3 Statistical analysis 
Chi-square tests (p<0.05; 95% confidence interval) were used to compare the proportion of correct/incorrect 
answers and the proportion of A&S in the PL of medicines from different: 1) therapeutic groups, 2) types of 
approval, 3) routes of administration, and 4) types of dispensing. SPSS (version 19) was used. 
3. Results 
In this section, the results of the descriptive and interpretation study are presented. 
3.1 Descriptive study 
A total of 828 different A&S (6407 occurrences) were identified in the 531 PL. The most prevalent groups of 
A&S were units of measures and chemical symbols (Table 1). 359 A&S (43.4% of 828) occurred only once (e.g. 
2½). By contrast, 92 A&S (11.1% of 828) occurred more than 12 times (e.g. mg, E171). An average of 12.1 A&S 
(SD = 13.1) per PL was found. 38% PL contained more than 10 A&S (whether different or not). PL from anti-
infective medicines (16 out of 45 PL) contained the highest proportion of A&S (more than 20 per PL), while the PL 
from dermatological medicines (34 out of 37 PL) contained the lowest proportion of A&S (less than 10 A&S per 
PL). 
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Table 1. Distribution of abbreviations and symbols 
 A&S Groups Number a % Occurrences % 
1 Units of measure 128 15.5 1521 23.7 
2 Chemical symbols 211 25.5 985 15.4 
3 Fractions or numbers in association with symbols 
or letters 
68 8.2 501 7.8 
4 Names of diseases 56 6.8 323 5.0 
5 Micro-organisms 53 6.4 189 2.9 
6 Drug names or therapeutic-related information 81 9.8 966 15.1 
7 Administration 18 2.2 147 2.3 
8 Information on anatomical and/or physiological 
issues
57 6.9 308 4.8 
9 Enzymes 42 5.1 201 3.1 
10 Mathematical or pharmacokinetic items 11 1.3 242 3.8 
11 Marks on the surfaces of medicines 55 6.6 73 1.1 
12 Common use 16 1.9 740 11.5 
13 Other 32 3.9 211 3.3 
 Total 828 100 6407 100 
a Number of different symbols and abbreviations in each group
The proportion of PL with more than 10 A&S in prescription-only medicines (41.1%, 174 of 423 PL) was 
statically greater that in OTC (23.1%, 25 of 108 PL) (Chi-Square = 13.4, p=0.004). Also, the proportion of PL with 
more than 10 A&S in medicines for parenteral administration (60.5%, 52 of 86 PL) was statistically greater than in 
oral preparations (37.3%, 116 of 311 PL), and other administration routes (23.1%, 31 of 134 PL) (Chi-Square = 
35.9, p<0.001). The proportion of A&S in the PL of medicines approved via centralized vs. non-centralized 
procedure was not statically different. Overall, 1618 A&S (25.1% of 6407) were non-compliant with the legal 
requirements (e.g. abbreviations with full correspondence in a language other than Portuguese, or use of ">" or "<") 
(Table 2).3,9,23
Table 2. Abbreviations and symbols non-compliant with the legal requirements 
 Occurrences % 
Abbreviations with full correspondence in English 783 12.2 
Fractions 294 4.6 
> or < 265 4.1 
Numerical dose and unit of measure run together 124 1.9 
Abbreviation of active substances 74 1.2 
μ 56 0.8 
U 22 0.3 
Other 4789 74.9 
Total 6407 100 
3.2 Exploratory interpretation study 
Because in 1 of the questionnaires the description of the meanings of the A&S was not given, and 7 had more 
than one third of errors in the control questions, 8 of the 26 initial questionnaires were excluded. The participants 
were mainly females (n=15, 83.3%), with an average age of 20.5 ± 2.7 (Table 2). A total of 3462 test questions were 
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answered, but only 343 (9.9%) were considered correct. In the majority of the cases, the participants immediately 
assumed not to know the A&S, and the null answers were rare. A total of 202 control questions were answered and 
156 (78%) were marked correct. The proportion of correct answers between the control and test questions was 
statistically significantly different (Chi-square = 549.7; p<0.001). A&S from units of measure (45 A&S) were 
correctly answered in 19.5% (122 out of 624 answers), and only 8.1% of the remaining types of A&S (234 out of 
2860 answers) were correct.  
4. Discussion 
The discussion is dived, as follow: general discussion, practical implications, and limitations. 
4.1 General discussion 
The results of the descriptive study show that A&S were widely used in the sampled PL, including A&S not 
compliant with the international regulation.13-15,22,23 Although these A&S are common in the glossaries of 
biomedical literature,19,22,23 their presence and/or their correspondent full meaning was infrequent in databases of 
common Portuguese.27 In addition, the results from the interpretation study confirmed a very limited understanding 
on these A&S by the participants, even for a group of subjects with a level of education higher than the secondary 
school. In fact, only in very few cases A&S in the PL may be expected to be understood due to their widespread use 
(e.g. HIV or human immunodeficiency virus). 
The PL with more A&S were those from the group of medicines for parenteral administration, prescription 
medicines and medicines highly used in Portugal (e.g. antibiotics), i.e. PL for which the readability is particularly 
important.32 The fact that some Portuguese PL are direct translations of PL from medicines available in other 
European countries, 3,9,13-15,29,30 also strongly suggest the widespread use of A&S in PL in use in other European 
countries. A significant number of A&S was not compliant with the regulatory requirements.3,9,13-15,29,30 For instance, 
some A&S were not standardized in accordance to the requirements of the European Directorate for the Quality of 
Medicines30,31 (e.g. IV. instead of i.v. for intravenous, or the high proportion of abbreviations with correspondence in 
other languages than Portuguese). Knowing that patients often can not interpret technical A&S,11,33,34 the presence of 
this type of items may be especially problematic for countries, such as Portugal, where the average level of 
education is still quite low.35. It is well known that the general population have difficulties in understanding PL 
information.36,37 The participants in this study were purposively selected from a higher literacy level. Despite their 
level of education, our subjects also showed great difficulty in understanding A&S. This type of items may thus 
pattern like other highly technical, specific and low frequent terms that tend to negatively impact on patients’ 
compreehsion11,36,37, and this is not overridden by a rather high level of education. 
Overall, the findings of the present study support a low readability of aspects of the sampled PL,14,16 a higher risk 
of misinterpretations, and consequently additional issues for patients’ safety. Reducing the use of A&S in PL is 
required in order to improve readability, thus contributing to assure patients’ comprehension of the information 
conveyed by unfamiliar A&S, such as some units of measure internationally accepted (e.g. mmole).27 Additionally, 
software applications may be used, like PreText, to automatically screen A&S in PL in order to contributing to 
ensure their readability and regulatory compliance. It is expected that health professionals (e.g. physicians, 
pharmacists and nurses) will also benefit from a more appropriate and clear explanation of the technical A&S. The 
findings of this study may be contribute to improve the readability and quality of Portuguese PL, with possible 
extensions to PL in use elsewhere in Europe, since some Portuguese PL are direct translations of PL found in other 
European countries. 
4.2 Practical implications 
Information design techniques should be developed in order to improve the intelligibility of PL, which should 
include the limitation in the use of A&S, together with other procedures, such as a systematic reduction of the use of 
jargon (technical and scientific terms) or the presence of a website where people may improve a certain PL. The use 
of A&S should be strictly supervised by the medicine agencies, and some marketed PL seem to require revision. 
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Automatic methods for translations involving text mining and the detection of improper use of A&S or jargon may 
be useful in the present or new PL. 
4.3 Limitations 
Contrary to the legal recommendations, patients were not enrolled in the comprehension study.3 The A&S were 
isolated tested in the interpretation study and not inserted in the original PL text, and this means that the study is not 
entirely ecological in the sense that it does not reproduce the exact conditions of PL potential users. The number of 
participants may be considered rather low. The participants were asked to provide a brief explanation of the meaning 
of the A&S in the final column, and this may have dissuaded responders from admitting that they knew a particular 
A&S.  
5. Conclusion  
A substantial number of A&S non-compliant with the legal requirements were identified in the sampled PL.  
Moreover, it was found that a substantial number of A&S was not understood by a group of people with a rather 
high level of education. It seems therefore advisable to reduce and optimize this type of items in PL. Software 
applications may be useful in the development and validation of PL before the medicine reaches the market. Health 
authorities should supervise more strictly the occurrence of A&S with negative impact in PL readability. 
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